Alios nabs $8.4M to treat viruses
South San Francisco-based Alios BiopPharma just brought in $8.4 million in first-round funding from Novo, Novartis BioVentures and Roche Finance, according to peHUB. The company develops treatments for viruses by activating various parts of the normal human immune system.
Next Story: Sega, facing losses in games and amusement centers, lays off 560
Previous Story: HX Diagnostics lands $3.1M to diagnose infectious disease
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
